In a patient with positive antinuclear antibody (ANA) and anti‑U1‑RNP antibodies and an elevated high‑sensitivity C‑reactive protein (hs‑CRP), what is the most likely diagnosis and what initial diagnostic work‑up and management should be undertaken?

Most Likely Diagnosis: Mixed Connective Tissue Disease (MCTD) or Systemic Lupus Erythematosus (SLE)

The combination of positive ANA and anti-U1-RNP antibodies most strongly suggests either MCTD or SLE, with the elevated hs-CRP indicating active inflammation that requires immediate diagnostic clarification through specific clinical features and additional autoantibody testing.

Diagnostic Approach

Initial Clinical Assessment - Key Discriminating Features

The presence of anti-U1-RNP antibodies occurs in 25-30% of SLE patients but is mandatory for MCTD diagnosis 1, 2. To distinguish between these conditions, systematically evaluate for the following clinical features:

Features Favoring MCTD:

• Scleroderma-spectrum manifestations 1:
  • Swollen hands (puffy fingers)
  • Sclerodactyly
  • Gastroesophageal reflux disease
  • Raynaud's phenomenon (present in 91% of anti-U1-RNP patients) 1
• Esophageal dysmotility

If these scleroderma features are present, MCTD is the more likely diagnosis 1.

Features Favoring SLE:

• Absence of scleroderma features strongly suggests SLE rather than MCTD 1
• Younger age at presentation (mean ~37 years) 3
• Higher prevalence in Black patients (60%) 3
• Hematologic abnormalities (lower eosinophil, lymphocyte, monocyte counts) 4

Critical Diagnostic Work-Up

Essential Laboratory Testing:

1. Anti-dsDNA antibodies 5:

   • Use double-screening strategy: solid-phase assay (SPA) first, then Crithidia luciliae immunofluorescence test (CLIFT) for confirmation
   • Positive anti-dsDNA strongly supports SLE over MCTD

2. Complete anti-ENA panel 5:

   • Anti-Sm (specific for SLE)
   • Anti-Ro52 (if positive with anti-U1-RNP, increases risk of glomerulonephritis and pericarditis) 3
   • Anti-La/SSB
   • Note: Anti-RNP70 subtyping adds limited clinical value 4

3. Complement levels (C3, C4) 5:

   • Low complement suggests active SLE
   • Anti-C1q antibodies (if lupus nephritis suspected)

4. Antiphospholipid antibodies 5:

   • Anticardiolipin
   • Anti-β2-glycoprotein I
   • Lupus anticoagulant
   • Present in 30-40% of SLE patients

5. Complete blood count with differential 4

6. Urinalysis with microscopy - screen for glomerulonephritis

7. Hepatic function panel - rule out alternative causes of elevated CRP 6

Regarding the Elevated hs-CRP:

The elevated hs-CRP indicates active inflammation. Before attributing this solely to autoimmune disease, exclude acute infection by:

• Taking temperature
• Screening for infection/injury symptoms
• If CRP >50 mg/L, strongly consider acute infection 6
• Consider interferon gamma-induced protein-10 testing if available 6

Important caveat: CRP >10 mg/L is not always indicative of acute infection and can reflect chronic inflammation from autoimmune disease, obesity, or lifestyle factors 6.

Organ-Specific Evaluation

Based on anti-U1-RNP positivity, assess for:

1. Pulmonary involvement (occurs in 45% of anti-U1-RNP patients) 3:

   • High-resolution chest CT
   • Pulmonary function tests with DLCO
   • Screen for pulmonary arterial hypertension (echocardiogram)

2. Cardiac involvement 3:

   • Echocardiogram (pericarditis occurs in 40% with anti-U1-RNP)
   • ECG

3. Musculoskeletal 1, 3:

   • Joint examination (arthritis in 60% of anti-U1-RNP patients)
   • Consider muscle enzymes (CK, aldolase) if weakness present
   • Muscle biopsy may show necrotizing changes in 57% 3

4. Renal 3:

   • Glomerulonephritis occurs in 25% but only with coexisting anti-Ro52
   • Urine protein-to-creatinine ratio

5. Nailfold capillaroscopy - may show changes typical of MCTD/scleroderma spectrum 2

Management Approach

If MCTD Diagnosed:

• Treat based on organ involvement
• NSAIDs/low-dose corticosteroids for arthritis
• Immunosuppression (hydroxychloroquine, methotrexate, mycophenolate) for severe manifestations
• Calcium channel blockers for Raynaud's
• Monitor for pulmonary arterial hypertension

If SLE Diagnosed:

• Apply 2019 ACR/EULAR classification criteria
• Hydroxychloroquine as baseline therapy
• Corticosteroids for active disease
• Steroid-sparing immunosuppression based on organ involvement
• Monitor with anti-dsDNA and complement levels (not ANA) 5

Common Pitfalls to Avoid:

• Do not repeat ANA testing for monitoring - it is not cost-effective and does not correlate with disease activity 5
• Do not assume anti-RNP70 positivity distinguishes MCTD from SLE - it has limited discriminatory value 4
• Do not exclude CRP >10 mg/L automatically - evaluate clinical context first 6
• Do not overlook coexisting anti-Ro52 - this combination predicts glomerulonephritis and pericarditis risk 3
• In patients meeting both MCTD and SLE criteria (occurs in 61% of MCTD patients), the presence of scleroderma features should guide classification toward MCTD 1

Prognosis Considerations:

Anti-U1-RNP positivity in SLE is associated with 4:

• Less organ damage accrual over time
• Younger age at diagnosis
• Hematologic involvement
• Clinical phenotype resembling MCTD

However, anti-U1-RNP patients with arthritis may develop more aggressive, erosive disease 7.